低渗对比剂迟发不良反应的发生率与危险因素:一项10540次暴露的前瞻性观察研究
该研究在单家三级医院5周内监测所有接受低渗对比剂增强CT患者的迟发不良反应,共10540次暴露中迟发反应207次(2.0%),90.9%发生在一周内;既往药物过敏史(OR=4.59)和过敏性疾病(OR=2.54)是危险因素;预用药使复发率从8.5%降至1.7%(8/94 vs 3/178,p=0.016),更换对比剂与复用原对比剂无差异(2/38 vs 9/234,p=0.655)。
要点
- 迟发不良反应发生率为2.0%(207/10540),其中90.9%发生在一周内,9.1%在第20天前出现。
- 既往药物过敏史(OR=4.59,95%CI 2.17-9.71)和过敏性疾病(OR=2.54,95%CI 1.32-4.91)是迟发反应的危险因素。
- 预用药使复发率从8.5%降至1.7%(8/94 vs 3/178,p=0.016),但更换对比剂与复用原对比剂无差异(2/38 vs 9/234,p=0.655)。
核心结论
- 低渗对比剂迟发不良反应多发生在一周内;预用药可能有助于减少迟发反应的复发。
研究设计与样本
- 前瞻性观察研究,单家三级医院5周研究期内所有接受低渗对比剂增强CT的患者,共10540次暴露;第1天及第7至28天监测迟发反应,发生迟发反应者随访三年。
诊断标准与关键数值
- 总不良反应315次(3.0%),其中急性不良反应108次(1.0%),迟发不良反应207次(2.0%)。
- 迟发不良反应中90.9%发生在一周内,9.1%在之后至第20天前出现。
- 既往药物过敏史:OR=4.59(95%CI 2.17-9.71);过敏性疾病:OR=2.54(95%CI 1.32-4.91)。
- 有迟发反应史者,复发风险随暴露间隔延长而降低(OR=0.86,95%CI 0.77-0.97,p=0.025),使用抗组胺药预用药降低复发风险(OR=0.27,95%CI 0.06-0.99,p=0.049)。
临床应用与阅片要点
- 对有既往药物过敏史或过敏性疾病的患者,应关注迟发不良反应的可能性。
- 对有迟发反应史者,预用药可能有助于降低复发率;更换对比剂与复用原对比剂相比未见差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the incidence and risk factors of late adverse reactions (ARs) to non-ionic low-osmolar contrast media (LOCM).
METHODS: The occurrence of late AR was monitored on day 1 and from day 7 to day 28 in all patients who received enhanced computed tomography using LOCM during a 5-week study period in a single tertiary hospital. Patients who experienced late AR were followed up for three years.
RESULTS: Among the total 10,540 LOCM exposures, 315 ARs (3.0%) were reported; acute ARs occurred in 108 LOCM exposures (1.0%) and late ARs occurred in 207 LOCM exposures (2.0%) (90.9% within one week, 9.1% developed afterwards by day 20). Previous history of drug allergy (odds ratio [OR] = 4.59; 95% confidence interval [CI] 2.17-9.71) and allergic diseases (OR = 2.54; 95% CI 1.32-4.91) were risk factors of late ARs to LOCM. Although the recurrence rate was lowered with premedication from 8.5% to 1.7% (8/94 vs. 3/178; p = 0.016), LOCM change did not make difference compared to reuse of the culprit LOCM (2/38 vs. 9/234; p = 0.655). In patients with a history of late AR to LOCM, the risk of recurrent reactions decreased with longer time intervals between exposures (OR = 0.86; 95% CI: 0.77-0.97; p = 0.025) and with the use of antihistamine premedication (OR = 0.27; 95% CI: 0.06-0.99; p = 0.049).
CONCLUSIONS: Late ARs to LOCM occurred mostly within one week. The use of premedication may be helpful in reducing the recurrence of late ARs.
引用
- Kang, Lee, Ahn, et al. Incidence and risk factors of late adverse reactions to low-osmolar contrast media: A prospective observational study of 10,540 exposures. Eur J Radiol. 2021. PMID: 34952368. doi:10.1016/j.ejrad.2021.110101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。